Skip to main content
Default Image

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine

Citing The Democracy Collaborative’s Dana Brown on the need for a public option for pharmaceutics, this case study of rVSV-ZEBOV underscores the significant public contribution to the R&D of vaccines even under conditions of precarity, and suggests that an alternative approach to generating knowledge and developing interventions, such as open science, is required in order to fully realize the public sector’s contribution to improved global health.

“One option, which is gaining interest, is to create a ‘public option,’ that is, a public sector led supply of essential, affordably priced medicines from discovery all the way through manufacturing and regulatory approval.[55] Indeed, the case of rVSV-ZEBOV shows that such a public option is not simply theoretical; rather, as demonstrated by the NML, the public sector has the capacity to do much more than pure discovery research. Armed with sufficient resources, public sector labs can conduct phase 1, 2, and 3 clinical trials as well as solve many of the technical challenges that manufacturing a clinical grade vaccine will entail.”

Publication date: 2020-01-16
Parent publication: Journal of Law and the Biosciences
Publication URL:

More related work

March 19, 2020
Default Image

Protect the vulnerable, advance the democratic economy: Our statement on the COVID-19 crisis

We are in a period of breakdown, in which all that is wrong with the current system is now being laid bare. Rather than rebuild what we now clearly see should never have been, we must lead the construction out of this crisis of something new.

read more
March 18, 2020
Default Image

HAN Public Comments on Fair Housing Act Proposed Changes

The Healthcare Anchor Network submitted public comments to the Department of Housing and Urban Development (HUD), expressing our opposition to HUD’s proposed changes to the 2015 Affirmatively Furthering Fair Housing rule.

read more
March 17, 2020
An array of prescription medications on shelves

Online press briefing: Vaccines—The COVID-19 Case for Public Pharmaceutical Research and Development

Leading experts believe that it is the government’s responsibility to ensure widespread access to safe and effective vaccines that are developed with taxpayer money. In this virtual press briefing, hear why the U.S. government should develop and manufacture vaccines and other essential medicines so that we get the medicines we need, when we need them and at prices we can afford.

read more